Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score
- 3 July 2009
- journal article
- research article
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 17 (4), 303-310
- https://doi.org/10.1177/1066896909340274
Abstract
Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptor—positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycle—related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.Keywords
This publication has 15 references indexed in Scilit:
- Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast CancerAnnals of Surgical Oncology, 2009
- Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast CancerClinical Chemistry, 2007
- Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast CancerJNCI Journal of the National Cancer Institute, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Measurement of Gene Expression in Archival Paraffin-Embedded TissuesThe American Journal of Pathology, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expressionThe Prostate, 1995